Immuncell-LC
Phase 3Biologic
Immuncell-LC is one of 75 biologic programs targeting Liver Transplant. It is currently in Phase 3.
2
Indications
6
Total Trials
1
Active Trials
74
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Gemzar
GGynecologic Oncology Group
Preclinical
Immuncell-LC
GGC Cell Corporation
Phase 3
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
Active Comparator
ModernaPreclinical
LDE225
NovartisPreclinical
Sulfonylureas
Eli LillyPreclinical
Thiazolidinediones
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Survival1 trial
Liver Transplant1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Immuncell-LC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- GGC Cell Corporation